Journal article

Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.

Thomas A Rasmussen, Lakshmi Rajdev, Ajantha Rhodes, Ashanti Dantanarayana, Surekha Tennakoon, Socheata Chea, Tim Spelman, Shelly Lensing, Rachel Rutishauser, Sonia Bakkour, Michael Busch, Janet D Siliciano, Robert F Siliciano, Mark H Einstein, Dirk P Dittmer, Elizabeth Chiao, Steven G Deeks, Christine Durand, Sharon R Lewin

Clin Infect Dis | Published : 2021


BACKGROUND: Antibodies to programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may perturb human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) by reversing HIV latency and/or boosting HIV-specific immunity, leading to clearance of infected cells. We tested this hypothesis in a clinical trial of anti-PD-1 alone or in combination with anti-CTLA-4 in people living with HIV (PLWH) and cancer. METHODS: This was a substudy of the AIDS Malignancy Consortium 095 Study. ART-suppressed PLWH with advanced malignancies were assigned to nivolumab (anti-PD-1) with or without ipilimumab (anti-CTLA-4). In samples obtained preinfusion and 1 an..

View full abstract


Awarded by American Foundation for AIDS Research

Awarded by Australian National Health and Medical Research Council

Awarded by NIDCR NIH HHS

Awarded by NCI NIH HHS